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Background: Deficiencies in membrane polyunsaturated fatty acids (PUFA) such as 
omega-3 (n-3) fatty acids are thought to contribute to the pathophysiological processes 
underlying psychotic disorders. Emerging evidence suggests that the levels of PUFA are 
related to clinical symptoms but significant heterogeneity exists between studies. Here, 
we investigated associations of membrane PUFA with clinical symptoms and functioning 
in a large sample of individuals at ultra-high risk (UHR) for psychosis.
Methods: A total of 285 participants of the NEURAPRO clinical trial were investigated for 
erythrocyte PUFA levels, including the n-3 index, n-6/n-3 PUFA ratio, docosahexaenoic 
acid (DHA), and eicosapentaenoic acid (EPA). Severity of general psychopathology [Brief 
Psychiatric Rating Scale (BPRS)], psychotic symptoms (BPRS psychosis subscale), 
negative symptoms [Scale for the Assessment of Negative Symptoms (SANS)], manic 
symptoms [Young Mania Rating Scale (YMRS)], depressive symptoms [Montgomery Asberg 
Depression Rating Scale (MADRS)], and functioning [Social and Occupational Functioning 
Scale (SOFAS), Global Functioning Social (GF-S) and Role (GF-R) scales] were assessed 
concurrently. Partial correlation taking into account the effects of gender, age, and smoking 
was used to examine the relationship between PUFAs and symptoms severity.
Results: The n-3 index negatively correlated with the severity of general psychopathology, 
psychotic symptoms, depressive symptoms, and manic symptoms. The n-6/n-3 PUFA 
ratio positively correlated with severity of psychotic and depressive symptoms. The n-3 
PUFA DHA negatively correlated with the severity of general psychopathology, positive, 
manic, and depressive symptoms. EPA negatively correlated with manic symptoms. 
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Nervonic acid, an n-9 monounsaturated fatty acid, positively correlated with general 
psychopathology, positive and negative symptoms, depressive symptoms, and manic 
symptoms. The long-chain saturated fatty acid tetracosanoic acid positively correlated 
with general psychopathology, positive, manic, and depressive symptoms.
Conclusions: Partially consistent with a previous study, psychotic symptoms, depressive 
symptoms, and symptoms of mania were associated with several classes of FAs in the 
present study. These findings support the relevance of membrane fatty acids for the onset 
of psychotic symptoms and indicate that FAs should be further evaluated as biomarkers 
in the UHR for psychosis group.
Clinical Trial Registration: ANZCTR, identifier: 12608000475347
Keywords: ultra-high risk, omega-3 fatty acids, psychosis, psychopathology, outcomes
INTRODUCTION
Young people at ultra-high risk (UHR) for psychosis have an 
elevated risk of developing psychosis of about 20% within 2 years and 
a significant risk for non-psychotic disorders (1, 2). The biological 
correlates underlying this risk state remain poorly understood but 
emerging evidence suggests the involvement of brain structural 
and functional alterations as well as peripheral pathology including 
immune activation, oxidative stress, endocrine abnormalities and 
deregulation of membrane lipid metabolism (3, 4). Given that it is 
currently unclear how to determine the biological risk for psychosis 
transition and other clinically relevant outcomes and how to develop 
treatments that target specific pathophysiological processes, it is 
important to elucidate the biological processes accompanying the 
UHR state. Moreover, declining transition rates in individuals who 
are clinically identified as being at UHR for psychosis (5) as well 
as uncertainty about the efficacy of specific interventions (6, 7) 
further add to the need to refine and improve risk prediction and 
consequently the identification of predictive biomarkers.
Deficits in long-chain omega-3 (n-3) polyunsaturated fatty acids 
(PUFAs) are one mechanism thought to contribute to psychosis risk 
(8, 9). In fact, n-3 PUFAs are integral components of the lipid bilayer 
forming the cell membrane and are found in high abundance in the 
human brain (10). There, they modulate the rigid formation of tightly 
packed saturated fatty acids through their structural characteristics, 
thereby also contributing to the biophysical properties of the 
neuronal membrane (11, 12). These in turn affect the function of ion 
channels and neurotransmitter receptors. Importantly, n-3 PUFA are 
essential fatty acids, meaning that their abundance in cell membranes 
is determined by intake from food and metabolic conversion. The 
lipid derivates of n-3 PUFA include anti-inflammatory eicosanoids 
such as resins and resolvins, which mediate the effects of n-3 PUFA 
on immune function (13, 14). Molecules derived from n-6 PUFA 
in contrast are known to have pro-inflammatory properties. First 
postulated by Horrobin et al. (15), the phospholipid structure of the 
cell membrane may be altered in schizophrenia and such alterations 
may contribute to various aspects of the pathophysiology observed in 
psychotic disorders, including neurotransmission, immune activation, 
and antioxidative defense. This is supported by studies showing 
n-3 PUFA deficiency in patients with schizophrenia compared to 
controls (16). Much less is known about the UHR for psychosis state, 
but evidence suggests lower levels of several n-3 and n-6 PUFA (17). 
Additionally, the balance between n-3 and n-6 PUFA, which is often 
seen as an indicator of immune activation, seems to be associated with 
depression in young people at UHR for psychosis (18).
More recently, clinical trials have tested the efficacy of n-3 PUFA 
for the prevention of psychosis transition in UHR individuals 
(19–21). While the first single-center trial showed significant 
benefits of n-3 PUFA over placebo in terms of the transition to 
psychosis risk (19), a multicenter replication study failed to show 
significant effects of n-3 PUFA supplementation on the transition 
rate (21). Possible reasons for the failure to replicate a reduction of 
transitions include true inefficacy of n-3 PUFA in this particular 
outcome measure, the background intervention of high-quality 
psychosocial care in both groups that may have created a ceiling 
effect, the use of antidepressants, or the high rate of non-adherence 
(57%) (22). Importantly, investigating the relationship between 
pre-treatment PUFA levels and symptom measures can provide 
further insight into potential mechanisms underlying lipid biology 
in regard to psychosis risk. A secondary analysis of the original 
single-center trial revealed associations of several classes of fatty 
acids with clinical symptoms and psychosocial functioning (23). 
In light of these observations, it seems important to replicate the 
findings of the original trial in the larger sample of the NEURAPRO 
clinical trial.
The aim of the present analysis was to examine associations 
of the cell membrane levels of fatty acids with clinical symptoms 
and functioning at baseline (i.e., prior to the intervention) in the 
NEURAPRO RCT. Specifically, we hypothesized that the n-3 
index would be associated with less severe symptoms and better 
functioning. Given the limited evidence for fatty acid variations 
in the UHR stage, we did not formulate specific hypotheses for 
other fatty acid classes.
METHODS
Participants
The study cohort consisted of 285 of 304 (94%) participants in the 
NEURAPRO study who provided consent for additional biomarker 
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analysis. NEURAPRO was a double-blind  placebo- controlled 
randomized clinical trial of fish oil (1.4 g fish oil/day) in people 
at UHR for psychosis (21) (ANZCTR identifier: 12608000475347) 
with 10 study sites (Amsterdam, Basel, Copenhagen, Jena, Hong 
Kong, Melbourne, Singapore, Sydney, Vienna, and Zurich). The 
intervention was administered in addition to cognitive behavioral 
case management (CBCM) for 6 months followed by a 6-month 
follow-up period. Help-seeking individuals attending UHR 
services in the trial centers were eligible if they were aged 13–40 
years and met UHR criteria (24, 25). Exclusion criteria were a 
previous psychotic episode, acute intoxication, organic brain 
disease, serious developmental disorder, abnormal coagulation 
profile or thyroid function, physical illness with a psychotropic 
effect, current treatment with mood stabilizers, past neuroleptic 
exposure to a total lifetime haloperidol equivalent dose of more 
than 50 mg, IQ of less than 70, dangerous behavior, aggression 
or suicidality, pregnancy, or current supplementation with n-3 
PUFA (25). All participants provided written informed consent 
(parent/guardian consent for participants aged <17 years). The 
NEURAPRO study was approved by the local human research 
ethics committees of the study centers.
Data Collection
Psychiatric symptoms at baseline were assessed with the Brief 
Psychiatric Rating Scale (BPRS), the Scale for the Assessment of 
Negative Symptoms (SANS), the Montgomery Asberg Depression 
Rating Scale (MADRS) for depressive symptoms, the Young 
Mania Rating Scale (YMRS) for manic symptoms, the Social 
and Occupational Functioning Scale (SOFAS), and the Global 
Functioning Social (GF-S) and Role (GF-R) scales.
Fatty Acid Analysis
Total fatty acid levels were quantified from erythrocyte samples 
collected at baseline. Erythrocytes were separated from plasma 
and extracted using an automated extraction method described 
previously in Ref. (26). Fatty acid levels were measured using 
mass spectrometry utilizing a hybrid triple quadrupole linear ion 
trap mass spectrometer (QTRAP 5500 AB Sciex, MA, USA) with 
an automated chip-based nanoelectrospray source (TriVersa 
NanoMate, Advion BioSciences, New York, USA). Ionized 
lipids identified with a minimum signal-to-noise ratio of 10 
were included in the analysis. Identification and quantification 
were accomplished using LipidView (v1.2, Sciex, MA, USA). 
Quantification was performed using LipidView software by 
comparing the spectral peak area of individual lipids to their 
class-specific internal standards following isotope correction.
Statistical Analysis
The n-3 index was calculated as the proportion of 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) 
relative to the total amount of n-3 fatty acids. The n-6/n-3 PUFA 
ratio was calculated as arachidonic acid (AA) divided by the 
sum of EPA and DHA. To examine the relationship between 
PUFA and psychopathology, partial correlation coefficients 
(adj. R) were calculated adjusting for age, gender, and smoking, 
as these covariates have been found to influence both fatty acid 
levels and psychopathology. Given the explorative nature of the 
study and the fact that variations in PUFA concentrations in the 
UHR stage is still in a hypothesis-generating phase, we did not 
to correct for multiple testing. The significance for all tests was 
set at α < 0.05. Stata 13.1 (StataCorp, College Station, TX, USA) 
for Mac OS was used for all analyses.
RESULTS
Relevant demographic and psychological variables are presented 
Table 1. The sample comprised 285 participants (mean age 
19.0 years ± 4.5; 45.26% male).
Partial correlations between fatty acids and related indices 
and psychological variables, adjusted for age, gender, and 
smoking, are reported in Table 2. BPRS scores were positively 
correlated with one saturated FA [tetracosanoic acid (24:0), p < 
0.001], one n-9 fatty acid [nervonic acid (NA) (24:1), p < 0.001] 
and the n-6/3 PUFA ratio (p = 0.01), and negatively correlated 
with the n-3 index (p = 0.003), two n-3 FAs [dihomo-y-linolenic 
acid (20:3), p = 0.010 and DHA (22:6), p < 0.001], and two n-6 
FAs [AA (20:4), p = 0.037 and linoleic acid (18:2), p < 0.001]. The 
BPRS psychotic symptoms sub-scale was positively correlated 
with one n-9 fatty acid [NA (24:1), p = 0.009] and the n-6/3 
PUFA ratio (p = 0.01), and negatively correlated with one n-6 FA 
[linoleic acid (18:2), p = 0.04], the n-3 index (p = 0.008). Negative 
symptoms (SANS) were positively correlated with one saturated 
FA [tetracosanoic acid (24:0), p < 0.001] and one n-9 FA [NA 
(24:1), p < 0.001] and negatively correlated with one saturated 
FA [palmitic acid (16:0), p < 0.001], two n-6 FAs [dihomo-y-
linolenic acid (20:3), p < 0.001 and linoleic acid (18:2), p < 0.001], 
and one n-7 FA [vaccenic acid (18:1), p = 0.004].
YMRS scores were positively correlated with tetracosanoic 
acid [(24:0), p < 0.0001] and one n-9 FA [NA (24:1), p < 0.0001] 
and negatively correlated with three n-3 FAs [dihomo-y-linolenic 
acid (20:3), p = 0.002; EPA (20:5), p = 0.03; and DHA (22:6), 
p < 0.0001] two n-6 FAs [linoleic acid (18:2), p < 0.0011 and AA 
(20:4), p < 0.0001], and the n-3-index (p < 0.0001). MADRS scores 
were positively correlated with one saturated FA [tetracosanoic 
TABLE 1 | Demographic and clinical characteristics and inflammatory markers  
of 285 NEURAPRO study participants. 
Age, mean (SD) 18.97 (4.49)
Sex
 Female, n (%) 156 (54.74)
 Male, n (%) 129 (45.26)
Smoking, n (%) 110 (38.6)
BPRS, mean (SD) 41.02 (9.72)
SANS, mean (SD) 17.79 (12.81)
MADRS, mean (SD) 19.27 (8.97)
SOFAS, mean (SD) 53.30 (12.44)
GF-S, mean (SD) 6.51 (1.22)
GF-R, mean (SD) 5.95 (1.54)
BPRS, Brief Psychiatric Rating Scale; MADRS, Montgomery-Asberg Depression Rating 
Scale; SANS, Scale for the Assessment of Negative Symptoms; SOFAS, Social and 
Occupational Functioning Scale.
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acid (24:0), p < 0.0001], one n-9 FA [NA (24:1), p < 0.0001], and 
the n-6/3 PUFA ratio (p = 0.005), and negatively correlated with 
the n-3-index (p = 0.002), two n-3 FAs [dihomo-y-linolenic acid 
(20:3), p = 0.001 and DHA (22:6), p = 0.001], two n-6 FAs [linoleic 
acid (18:2), p < 0.0001 and AA (20:4), p = 0.03], and one n-7 FA 
[vaccenic acid (18:1), p = 0.03]. SOFAS scores were negatively 
correlated with one saturated FA [stearic acid (18:0), p = 0.031]. 
GF-S scores were positively correlated with one n-6 FA [linoleic 
acid (18:2), p < 0.01] and one n-3 FA [dihomo-y-linolenic acid 
(20:3), p = 0.01]. Finally, GF-R scores were positively correlated 
with one saturated FA [margaric acid (17:0), p = 0.02], one n-7 FA 
[vaccenic acid (18:1), p = 0.04], one n-6 FA [adrenic acid (22:4)], 
and one n-3 FA [dihomo-y-linolenic acid (20:3), p = 0.01].
DISCUSSION
The aim of this study was to investigate associations of cell 
membrane fatty acids with clinical characteristics in a large 
multicenter RCT of fish oil supplementation in individuals 
at UHR for psychosis. After taking into account the effects of 
age, gender, and smoking, we found several PUFAs related to 
psychopathology, including general psychopathology (BPRS), 
psychotic symptoms (BPRS), negative symptoms (SANS), manic 
symptoms (YMRS), and depressive symptoms (MADRS). The 
n-3 index, DHA, AA, dihomo-y-linolenic acid, and linoleic 
acid were negatively correlated with BPRS, MADRS, and YMRS 
scores, while the n-6/3 PUFA ratio was positively correlated with 
general psychopathology (BPRS), psychotic symptoms (BPRS), 
and depressive symptoms (MADRS). Tetracosanoic acid and NA 
in turn were significantly positively correlated with BPRS, SANS, 
MADRS, and YMRS scores. Collectively, these findings support 
the notion that several classes of fatty acids are associated with 
symptom severity in this group.
Our analysis contributes important insights into the 
relationship between PUFA and psychopathology by replicating 
findings of our previous smaller study in UHR (23) in a large (n = 
285) and well-characterized sample. Overall, our results confirm 
that higher levels of n-3 PUFA (n-3 index) correspond to fewer 
symptoms in this population. The n-3 index, representing the 
sum of EPA and DHA relative to other PUFA, was significantly 
associated with lower general psychopathology (BPRS) scores, 
which is broadly consistent with a previous study (27), as 
well as with lower manic (YMRS) and depressive (MADRS) 
symptoms. The n-6/n-3 PUFA ratio, reflective of the balance 
between n-3 and n-6 PUFA, was positively correlated with 
psychotic symptoms (BPRS) and MADRS scores, suggesting 
that a higher relative proportion of n-6 PUFA compared to n-3 
PUFA correlates with more severe symptoms. Consistent with 
the present findings, Kim et al. (23) found that the n-6/n-3 PUFA 
ratio was associated with psychotic symptoms, and the sum of 
n-3 PUFA negatively with negative symptoms. This suggests that 
the n-3 index is relevant to a range of symptoms in the UHR 
state. Consistent with this, DHA was also associated with lower 
BPRS scores in our study. DHA is the most abundant n-3 PUFA 
in the human brain and integral to the neuronal membrane. 
Importantly, erythrocyte DHA correlates with gray matter DHA TA
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(28) and may be particularly relevant during adolescence, where 
increases in the level of DHA may be critical for the development 
of the prefrontal cortex and cortical maturation more generally 
(29–31). Given that the UHR state and the onset of psychotic 
disorders fall within this developmental period in many cases, 
n-3 PUFA including DHA may play a particularly important role 
in this phase.
Our results also support an association of the n-3 index and 
the n-6/n-3 PUFA ratio with depressive symptoms in this UHR 
cohort. Considering that young people at UHR for psychosis 
have a high risk for depression of up to 42% (1), these findings 
are highly relevant to the UHR group. There is ample evidence to 
support n-3 PUFA deficiency in patients with major depressive 
disorders (32) and for the efficacy of n-3 PUFA as a potential 
treatment of depressive symptoms [see meta-analyses in Refs. 
(33–35)]. Moreover, we recently reported that in individuals at 
UHR for psychosis, a high n-6/n-3 PUFA ratio is predictive of 
depression within a 7-year follow-up (18). Our present findings 
support an association of the n-3 index as well as of DHA levels 
with depressive symptoms, thereby confirming previous results. 
However, EPA, the n-3 PUFA found to be most effective for 
the treatment of depression (34), was not related to depressive 
symptoms in this study.
In addition to n-3 PUFA, linoleic acid (18:2), an n-6 PUFA 
and precursor to arachidonic acid, EPA and DHA, was inversely 
associated with symptoms severity and positively associated 
with functioning. Previous studies examining the relationship 
between linoleic acid and psychopathology have yielded mixed 
results. For example, in a recent study of 154 patients with 
major depressive disorder, linoleic acid was found to be reduced 
compared to controls and inversely correlated with depressive 
symptoms severity (36). Similarly, in a population-based study 
of otherwise healthy adults, low levels of linoleic acid were 
associated with depressive symptoms (37). However, other 
studies found no association of linoleic acid with depression 
(38, 39). While our results suggest that linoleic acid is associated 
with fewer symptoms and better functioning, these observations 
warrant further confirmation.
An interesting observation in our study was that tetracosanoic 
acid (lignoceric acid; 24:0), a very long chain saturated fatty 
acid mainly found in peanut and canola oil (40), was strongly 
positively correlated with all symptom scores. Few studies to 
date have investigated saturated fatty acids in the UHR group. 
Of note, Hamazaki et al. (41) found elevated levels of these fatty 
acids in post-mortem brain tissue of patients with schizophrenia 
compared to controls.
The mechanisms linking deficits in n-3 PUFA with 
psychopathology in the UHR group are only partially understood 
but likely include effects on serotonergic and dopaminergic 
neurotransmission through the modulation of membrane 
fluidity and ion channel function (42), PUFA effects on HPA axis 
regulation and the regulation of antioxidative defense (43), as 
well as the production of pro- and anti-inflammatory derivatives 
of PUFA (14, 44, 45). EPA rapidly beta-oxidized once in the 
brain (46, 47), and oxidation products are not specific for EPA. 
Therefore, EPA effects in depression cannot be explained by 
effects in the brain; rather, peripheral anti-inflammatory effects 
may be relevant. EPA’s oxidation products are anti-inflammatory 
eicosanoids, and oxidative stress as seen in psychiatric disorders 
would only increase these. This is supported by Rapaport et al. 
(48), who showed that high inflammation is a predictor of 
response to n-3 PUFA supplementation.
Other fatty acids related to psychopathology in our study 
include NA. NA, an n-9 monounsaturated fatty acid, is abundant 
in the white matter of the central nervous system and important 
for the biosynthesis and maintenance of the myelin sheath. For 
example, the levels of NA (but also AA and DHA) were found 
to be related to decreased white matter integrity in the corpus 
callosum, parietal, occipital, temporal, and frontal lobes (49). 
Impaired myelin pathways and impairments in white matter 
integrity in the medial frontal lobe and other brain areas 
relevant to psychosis have been observed in individuals who 
later transitioned to psychosis (50). Decreased levels of NA 
have previously been observed in association with more severe 
psychotic symptoms and with higher transition risk (23, 51). The 
present findings seem difficult to reconcile as they suggest the 
opposite relationship. However, differences in the methodology 
between the present study and previous studies may explain 
these discrepancies (52). While Amminger et al. (51) measured 
NA from the phosphatidylethanolamine fraction of erythrocytes 
using gas chromatographic analysis, NA was quantified in 
this study from whole erythrocyte membranes using mass 
spectrometry. In patients with major depressive disorder, 
where white matter dysfunction is similarly hypothesized, both 
increases and decreases in NA have been observed (52, 53).
An important question not answered by our study is whether 
young individuals at UHR for psychosis show deficits in those 
n-3 PUFAs associated with more severe symptoms compared to 
healthy (non-UHR) individuals. To date, only one study of our 
group addressed this question and reported deficits in two n-3 
PUFAs and several n-6 PUFAs (17). We are currently investigating 
this question in the NEURAPRO trial and a matched control 
group. Studies in patients with chronic schizophrenia provided 
heterogeneous findings and showed decreases in AA, DPA, and 
DHA (54). However, several studies in schizophrenia patients 
including a more recent study showed increases in these fatty 
acids in patients compared to controls as well as in unaffected 
siblings compared to controls (55–57). Findings in youth at UHR 
for bipolar disorder showed deficits in the n-3-index compared to 
healthy controls (58, 59). It therefore seems important to clarify if 
low n-3 PUFA levels precede the onset of psychosis.
A strength of our study is the sample size, making this the 
largest examination of membrane PUFA in UHR to date. 
A second strength is the well-characterized sample and the 
availability of a variety of clinical measures. Limitations include 
the cross-sectional nature of this analysis, which precludes causal 
inferences. The effects sizes of several correlations reported 
here—while statistically significant—are small (adj. R < 0.2). 
Also, the selection of fatty acids measured is not fully consistent 
with a previous study (23) due to the choice of methods used 
for the analysis. The present study used mass spectrometry, a 
novel method recently published (26), while previous studies 
used mostly gas chromatography. While dietary habits were not 
considered here, we argue that membrane PUFA status is a valid 
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biological measure of lipid biology irrespective of source. Finally, 
we did not correct for multiple comparisons in the present study 
due to its exploratory nature.
Future studies should further confirm if the UHR for psychosis 
group has deficits in PUFA compared to healthy individuals 
as well as other high-risk groups; clarify causality by testing 
whether the relationship with clinical symptoms persists at 
follow-up and is predictive of treatment response and long-term 
remission; if supplementation with fish oil can reverse potential 
deficits and associations with psychopathology; and whether the 
relationship between lipid biology and symptoms is attributable 
to inflammation or other biological mechanisms that may serve 
as potential treatment targets.
In conclusion, our study confirms that membrane PUFAs are 
associated with the severity of clinical symptoms in individuals 
at UHR for psychosis. In particular, we found that the n-3 index 
was negatively correlated with multiple measures, including total 
BPRS scores, MADRS, and YMRS scores. These results suggest 
that n-3 PUFA are important in the pathophysiology of the UHR 
state and may indicate risk for poor mental health outcomes. 
Given that recent RCTs of n-3 PUFA in the UHR were unable to 
demonstrate superiority of n-3 PUFA over placebo for transition 
to psychosis, biomarker studies are warranted to clarify if low n-3 
PUFA levels predispose for adverse outcomes and are indicative 
of treatment response with n-3 PUFA. 
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